Literature DB >> 28138580

Sorafenib in adjuvant setting: call for precise and personalized therapy.

Wei Zhang1.   

Abstract

Entities:  

Year:  2016        PMID： 28138580      PMCID： PMC5244768          DOI： 10.21037/tgh.2016.03.13

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  23 in total

1.  Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Authors:  Jordi Bruix; Jean-Luc Raoul; Morris Sherman; Vincenzo Mazzaferro; Luigi Bolondi; Antonio Craxi; Peter R Galle; Armando Santoro; Michel Beaugrand; Angelo Sangiovanni; Camillo Porta; Guido Gerken; Jorge A Marrero; Andrea Nadel; Michael Shan; Marius Moscovici; Dimitris Voliotis; Josep M Llovet
Journal:  J Hepatol       Date:  2012-06-19       Impact factor: 25.083

Review 2.  A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.

Authors:  Tianqiang Song; Wei Zhang; Qiang Wu; Dalu Kong; Weiwei Ma
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-11       Impact factor: 2.566

3.  Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

Authors:  Masatoshi Kudo; Kazuho Imanaka; Nobuyuki Chida; Kohei Nakachi; Won-Young Tak; Tadatoshi Takayama; Jung-Hwan Yoon; Takeshi Hori; Hiromitsu Kumada; Norio Hayashi; Shuichi Kaneko; Hirohito Tsubouchi; Dong Jin Suh; Junji Furuse; Takuji Okusaka; Katsuaki Tanaka; Osamu Matsui; Michihiko Wada; Iku Yamaguchi; Toshio Ohya; Gerold Meinhardt; Kiwamu Okita
Journal:  Eur J Cancer       Date:  2011-09       Impact factor: 9.162

Review 4.  Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster.

Authors:  Giannis Mountzios; George Pentheroudakis; Peter Carmeliet
Journal:  Pharmacol Ther       Date:  2013-09-27       Impact factor: 12.310

5.  Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience.

Authors:  Wei Zhang; Gang Zhao; Kai Wei; Qingxiang Zhang; Weiwei Ma; Tianqiang Song; Qiang Wu; Ti Zhang; Dalu Kong; Qiang Li
Journal:  Biosci Trends       Date:  2014-12       Impact factor: 2.400

6.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Authors:  Riccardo Lencioni; Josep M Llovet; Guohong Han; Won Young Tak; Jiamei Yang; Alfredo Guglielmi; Seung Woon Paik; Maria Reig; Do Young Kim; Gar-Yang Chau; Angelo Luca; Luis Ruiz Del Arbol; Marie-Aude Leberre; Woody Niu; Kate Nicholson; Gerold Meinhardt; Jordi Bruix
Journal:  J Hepatol       Date:  2016-01-22       Impact factor: 25.083

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

9.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

10.  Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.

Authors:  Zhigui Guo; Manqing Cao; Abin You; Junrong Gao; Hongyuan Zhou; Huikai Li; Yunlong Cui; Feng Fang; Wei Zhang; Tianqiang Song; Qiang Li; Xiaolin Zhu; Huichuan Sun; Ti Zhang
Journal:  Cancer Sci       Date:  2016-02-23       Impact factor: 6.716
View more
  2 in total

1.  Characterization of the Tumor Immune Microenvironment Identifies M0 Macrophage-Enriched Cluster as a Poor Prognostic Factor in Hepatocellular Carcinoma.

Authors:  Mark Farha; Neil K Jairath; Theodore S Lawrence; Issam El Naqa
Journal:  JCO Clin Cancer Inform       Date:  2020-10

2.  Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma.

Authors:  Ming-Chin Yu; Tsung-Han Wu; Chao-Wei Lee; Yun-Shien Lee; Jang-Hau Lian; Chia-Lung Tsai; Sen-Yung Hsieh; Chi-Neu Tsai
Journal:  Biomed J       Date:  2020-07-15       Impact factor: 7.892
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.